Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced positive topline results from the investigational Phase 3 MajesTEC-9 study of TECVAYLI® ...

A new "double-pronged" CAR T immunotherapy recognizes two distinct features of multiple myeloma to destroy the cancer more ...

Treatment for stage 3 myeloma is typically divided into phases. The goal is to achieve a deep remission, meaning the cancer is undetectable. This is the first phase. Most patients receive a "triplet" ...

In A Nutshell Men have double the odds of presenting with stage III multiple myeloma compared to women, even after accounting ...

Discover the latest breakthroughs in multiple myeloma treatment, including CAR T-cell therapies and promising new options for relapsed patients. This year brought major advances across the multiple ...

Patients share their experiences on the importance of seeking second opinions and expert care in managing complex myeloma ...

By the time a Florida mom of two finally heard the words "multiple myeloma," she had already spent months being told her ...

Men are twice as likely as women to have stage III multiple myeloma at diagnosis and appear to have a greater tumor burden than women, according to ...

Large BIDMC-led study maps immune cells in myeloma tumors, improving risk prediction beyond genetics and helping identify ...

Longer-term results from the BENEFIT trial show sustained minimal residual disease negativity in newly diagnosed, ...

Higher levels of CD4-positive naïve T cells in patients receiving CAR T-cell therapy for multiple myeloma are associated with ...

Rates of multiple myeloma (MM), the second most common blood cancer in the United States, are increasing and are twice as ...